Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Evidence-based Treatment
100%
Clinical Practice Guidelines
100%
Central Serous Chorioretinopathy
100%
Eye Research
100%
Half-dose
27%
Half-dose Photodynamic Therapy
27%
Verteporfin
18%
Subretinal Fluid
18%
Treatment Options
9%
New Treatment Options
9%
Angiography
9%
Therapeutic Strategies
9%
Early Treatment
9%
Photodynamic Therapy
9%
Common Disease
9%
Paucity
9%
Macular
9%
Current Therapeutics
9%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
9%
Epithelial Layer
9%
Treatment Algorithm
9%
Intravitreal Injection
9%
Vision Loss
9%
Blood-retinal Barrier
9%
Non-central
9%
Fluid Leakage
9%
Vision-related Quality of Life
9%
Photosensitive Dye
9%
Retinal pigment Epithelial
9%
Reduced Vision
9%
Choroidal Abnormality
9%
Conventional Laser Photocoagulation
9%
Macular Neovascularization
9%
Medicine and Dentistry
Central Serous Retinopathy
100%
Photochemotherapy
36%
Verteporfin
18%
Subretinal Fluid
18%
Randomized Controlled Trial
9%
Retinal Pigment Epithelium
9%
Visual Impairment
9%
Angiography
9%
Vasculotropin
9%
Laser Coagulation
9%
Intravitreal Administration
9%
Choroid
9%
Blood-Retinal Barrier
9%
Low Vision
9%
Pharmacology, Toxicology and Pharmaceutical Science
Central Serous Retinopathy
100%
Photodynamic Therapy
36%
Verteporfin
18%
Subretinal Fluid
18%
Randomized Controlled Trial
9%
Visual Impairment
9%
Low Vision
9%
Visual Pigment
9%
Vasculotropin
9%
Neovascularization (Pathology)
9%
Intravitreal Administration
9%
Neuroscience
Central Serous Chorioretinopathy
100%
Verteporfin
18%
Randomized Controlled Trial
9%
Angiography
9%
Vascular Endothelial Growth Factor
9%
Choroid
9%
Blood Retina Barrier
9%
Visual Pigment
9%